Cost-Effectiveness of Nivolumab in Combination with Ipilimumab in First-Line Treatment of Advanced Melanoma in Sweden- Analysis Using 28-Month Overall Survival from Checkmate 067
Abstract
Authors
T Baker VF Paly J Sabater C Holmberg M Hultberg J Lundström R Minacori O Chirita